Invivyd Reports Full Year 2022 Financial Results and Business Highlights
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term... | March 23, 2023
Source: marketscreener.com